Overview

This trial is active, not recruiting.

Conditions non-small cell lung cancer, egfr, her-2
Treatment bibw 2992
Phase phase 2
Targets EGFR, HER2, HER4
Sponsor Instituto Nacional de Cancerologia de Mexico
Start date January 2012
End date June 2014
Trial size 66 participants
Trial identifier NCT01542437, BIBW2992

Summary

Patients with stage IIIB and IV lung adenocarcinoma and progression to first-line chemotherapy were enrolled to receive afatinib 40 mg/day. Mutational EGFR and HER-2 status were assessed by RT-PCR. HER2 amplification was evaluated by FISH. Plasma HGF levels were measured by ELISA before and 2 months (mo) after the start of treatment. We assessed changes in serum HGF levels and their association with objective response rate (ORR), PFS and overall survival (OS).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Endpoint classification safety/efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Patients received a daily oral 40mg dose of afatinib. Treatment was continued until docu-mented disease progression, unacceptable toxicity or withdrawal of consent. The Common Terminology Criteria for Adverse Events (CTCAE) v4.0 was used to evaluate toxicity. In patients with severe toxicity (grade ≥3) afatinib was temporary discontinued until the patient recovery to at least grade 1 toxicity and continued with a dose reduction to 30 mg/day. Dose reduction below 30mg/day was not allowed. Patients experiencing more than one grade ≥3 event, those with grade ≥2 toxicity after dose reduction, and/or those showing no recovery within 14 days discontinued treatment.
bibw 2992 Afatinib
All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria. Not to be compared with any other drug.

Primary Outcomes

Measure
Overall response
time frame: from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.
Progression Free Survival
time frame: from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.
Overall survival
time frame: from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.

Secondary Outcomes

Measure
Evaluation of the HER-2 gene copy number and amplification
time frame: Baseline
DNA Extraction and Mutational Analysis of EGFR and HER-2
time frame: Baseline
Toxicity evaluation
time frame: from the start of consumption until at least 6 months after stopping BIBW 2992 or when all patients have died.
Determination of plasma HGF pre and post-treatment concentration
time frame: Baseline and after 2 months of treatment.

Eligibility Criteria

Male or female participants from 18 years up to 90 years old.

Inclusion Criteria: - Diagnosis of lung cancer non-small cell (stage IIIB or IV) inoperable, locally advanced, recurrent or metastatic, histologically or cytologically documented. - The patient must present evidence of measurable disease. - 18 years of age or older. - ECOG performance status of 0-2 - Life expectancy at least 12 weeks. - lung cancer patients with advanced non-small cell, stage IIIB / IV who have received at least one cycle of systemic chemotherapy standard platinum-based first-or second-line fault has been documented that treatment. - are admissible 3 or more prior chemotherapy regimens. Patients must have recovered from any toxic effects and should have passed at least 2 weeks after the last dose prior to registration (14 days for vinorelbine and other vinca alkaloids or gemcitabine). Patients in the opinion of the investigator are fully recovered from surgery for 4 weeks at least, can also be considered for the study. Patients must have recovered from any severe toxicity (CTC ≤ 1) caused by any previous therapy. - granulocyte count ≥ 1.5x 109 / L and platelet count> 100 × 109 / L. - serum bilirubin should be ≤ 1.5 X ULN - AST and / or ALT ≤ 2 ULN (or ≤ 5 x ULN when clearly attributable to the presence of liver metastases). - Serum creatinine ≤ 1.5 (ULN) or creatinine clearance ≥ 60ml/min - Ability to comply with study procedures and monitoring. - Of all women of childbearing potential should be obtained a negative pregnancy test within 72 hours before the start of therapy. - Patients with reproductive potential must use effective contraception. - Written informed consent (signed) to participate in the study. Exclusion Criteria: - Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, liver disease, renal or metabolic). - Pre-treatment with systemic anti-tumor therapy with EGFR inhibitors (tyrosine kinase inhibitors). - Any other malignancy within the previous 5 years (except for carcinoma in situ of the cervix or skin cancer adequately treated basal cell type). - Excluded patients with brain metastases or spinal cord compression of newly diagnosed and / or have not been definitively treated with surgery and / or radiation, supporting both patients with CNS metastases or spinal cord compression previously diagnosed and treated with evidence of stable disease (clinically stable on imaging studies) for a minimum of 2 months. - Any significant ophthalmologic abnormality, especially severe syndrome of dry eye, keratoconjunctivitis sicca, Sjogren's syndrome, severe keratitis exposure and any other condition that may increase the risk of corneal epithelial damage. We do not recommend the use of contact lenses during the study. The decision to continue with the use of contact lenses should be discussed with the treating oncologist and the patient's ophthalmologist. - Patients unable to take oral medication, requiring intravenous nutrition, which have undergone prior surgical procedures affecting absorption, or who have active peptic ulceration. - lactating women.

Additional Information

Official title Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non Small Cell Lung Cancer in Advanced Stage, Which Have Progressed to Chemotherapy. Analysis of Mutations in EGFR and Number of Copies of HER-2
Principal investigator Oscar Arrieta, MD M Sc
Description Lung cancer is the main cause of cancer-related mortality worldwide, accounting for 1.6 million deaths in 2012. Non-small-cell lung cancer (NSCLC) histology comprises ap-proximately 85% of cases. At the time of diagnosis, 75% of the patients have locally advanced or metastatic disease, with a 5-year survival rate of less than 5%. Although treatment options for these patients remain limited, drugs targeting the epidermal growth factor receptor (EGFR) have proved to be a highly effective therapy in NSCLC patients harboring sensitizing EGFR mutations. Afatinib, a second-generation irreversible TKI, confers a theoretical advantage over re-versible TKIs in patients with acquired resistance. Through covalent binding to the kinase domain of EGFR, afatinib down regulates signaling from all homodimers and heter-odimers formed by ERBB receptor family members including EGFR, HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4). HER2 mutations in NSCLC are rare, being found in approximately 1-4% of lung adenocarcinomas. In contrast with reversible TKIs, the mechanisms of resistance to irreversible TKIs have not been fully elucidated, and identification of biomarkers that predict response to these drugs, particularly in patients progressing after first line therapy, is needed. In this study we assess the usefulness of plasma HGF concentrations as a predictor of response to afatinib in patients with advanced-stage lung adenocarcinoma.
Trial information was received from ClinicalTrials.gov and was last updated in July 2015.
Information provided to ClinicalTrials.gov by Instituto Nacional de Cancerologia de Mexico.